Author of

• 20167

  +

  P2.03 - Chemotherapy/Targeted Therapy (ID 704)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23278

    +

    P2.03-007 - Loxoprofen Prevents EGFR-TKI-Related Skin Rash in Non-Small Cell Lung Cancer Patients: A Single-Center Retrospective Study (ID 7539)

    09:30 - 09:30  |  Author(s): K. Imanaka
    • Abstract
    • Slides

    Background:
    Skin rash is the most common adverse event induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The efficacy of tetracycline for EGFR-TKI-related skin rash has been reported. However, a skin rash is often observed despite the use of tetracycline. Some studies have reported that skin rash is caused by a type of inflammation. Hence, there is a possibility that loxoprofen, a non-steroidal anti-inflammatory drug, can prevent these skin rashes.
    
    Method:
    We conducted a single-center, retrospective study to investigate the efficacy of loxoprofen for EGFR-TKI-related skin rash. The patients had non-small cell lung cancer and received EGFR-TKIs at the Chemotherapy Research Institute, Kaken Hospital from October 2011 to March 2017. We divided them into two groups: those who received EGFR-TKIs along with loxoprofen (loxoprofen (+) group; n = 12) and without loxoprofen (loxoprofen (−) group; n = 37), and investigated the incidence of EGFR-TKI-related skin rash.
    
    Result:
    There was no significant difference in the baseline characteristics between the groups. Grade 1 and 2 EGFR-TKI-related skin rash were more common in the loxoprofen (−) group than in the loxoprofen (+) group (grade 1; 90% versus 60%, P = 0.007, grade 2; 50% versus 0% P = 0.043, log-rank analysis). Multiple regression analysis indicated that the use of loxoprofen was a predictive factor that reduced the incidence of grade 1 skin rash (P = 0.0046). Figure 1
    
    
    
    Conclusion:
    Our study showed that loxoprofen combined with EGFR-TKIs could prevent skin rash, decreasing the risk by more than 65%. Our results suggest that loxoprofen can prevent and treat EGFR-TKI-related skin rash. Thus, we conclude that loxoprofen could be a new treatment option for EGFR-TKI-related skin rash.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.